A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 08 May 2008 Status changed from recruiting to completed.
- 12 Jan 2007 Status change
- 28 Nov 2006 New trial record.